var data={"title":"Sodium phenylbutyrate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium phenylbutyrate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6968?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-phenylbutyrate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium phenylbutyrate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=sodium-phenylbutyrate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sodium phenylbutyrate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221871\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Buphenyl</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27628435\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pheburane</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221884\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Urea Cycle Disorder (UCD) Treatment Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221872\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Urea cycle disorders:</b> Powder or tablet: Oral: 9.9 to 13 g/m<sup>2</sup>/day, administered in equally divided doses 3 to 6 times/day; safety and efficacy of doses &gt;20 g/day have not been established  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221879\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=sodium-phenylbutyrate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sodium phenylbutyrate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Urea cycle disorders:</b>  Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children &lt;20 kg: Powder: 450 to 600 mg/kg/day, administered in equally divided doses 3 to 6 times/day; safety and efficacy of doses &gt;20 g/day have not been established   </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children &ge;20 kg and Adolescents: Powder or tablet: Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221873\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22560101\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22560102\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221862\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buphenyl: (250 g) [contains sodium 125 mg/g]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: (250 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buphenyl: 500 mg [contains sodium 62 mg/tablet]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221850\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21987534\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Powder products: 1 level teaspoon provides 3 g sodium phenylbutyrate, 1 level tablespoon provides 8.6 g sodium phenylbutyrate. Measurers provided with the product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5674004\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer the total daily dose in equally divided doses with each meal or feeding (ie, 3 to 6 times/day).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Granules (Pheburane [Canadian product]): Measure dose using the dosing spoon provided which dispenses up to 3 g of sodium phenylbutyrate in graduations of 250 mg. The granules may be swallowed with a drink (eg, water, fruit juices, protein-free infant formulas) or sprinkled on solid food (eg, mashed potatoes or apple sauce). When mixed with food, the mixture should be administered immediately. Do not administer granules by tube; use a 50 mg/mL prepared solution,   administer with a syringe directly through the nasogastric or gastrostomy tube and rinse with water to clear tube.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Powder: May administer via mouth, gastrostomy tube, or nasogastric tube. Measure the dose using the teaspoon or tablespoon provided; one level teaspoon equals 3 g of sodium phenylbutyrate; 1 level tablespoon equals 8.6 g of sodium phenylbutyrate. The powder may be mixed with solid food, liquid food, or water. When mixed with food, the mixture should be used immediately; if mixed with water, the mixture may be stored at room temperature or refrigerated and must be used within 1 week. When mixing with a liquid, shake lightly prior to use; only sodium phenylbutyrate will dissolve, the excipients will not.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221863\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Urea cycle disorders:</b> Adjunctive therapy in the chronic management of patients with urea cycle disorder involving deficiencies of carbamoylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase; neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life); late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221857\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Endocrine &amp; metabolic: Amenorrhea (&le;23%), menstrual disease (&le;23%), acidosis (14%), hypoalbuminemia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Syncope (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Depression (&le;2%), headache (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Body odor (3%), skin rash (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Alkalosis (7%), hyperchloremia (7%), hypophosphatemia (6%), decreased serum total protein (3%), hyperuricemia (2%), hyperphosphatemia (2%), hypernatremia (1%), hypokalemia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (4%), dysgeusia (3%), abdominal pain (&le;2%), gastritis (&le;2%), nausea (&le;2%), vomiting (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (9%), leukocytosis (4%), leukopenia (4%), thrombocytopenia (3%), thrombocythemia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (6%), increased serum transaminases (4%), hyperbilirubinemia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal tubular acidosis (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Aplastic anemia, bruise, cardiac arrhythmia, constipation, dizziness, drowsiness, edema, fatigue, memory impairment, neuropathy (exacerbation), pancreatitis, peptic ulcer, rectal hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221865\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sodium phenylbutyrate or any component of the formulation; management of acute hyperammonemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy, breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221854\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fluid retention: May cause sodium and fluid retention; use with caution, if at all, in patients where fluid accumulation may be poorly tolerated, such as in HF.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperammonemia: Hyperammonemia and hyperammonemic encephalopathy may still occur while on therapy; manage acute hyperammonemia as a medical emergency. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: Signs and symptoms of neurotoxicity were observed at plasma concentrations &ge;3.5 mmol/L, including somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, impaired memory, and exacerbation of preexisting neuropathy; signs and symptoms were reversible upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Inborn errors of beta-oxidation: Use with caution in patients with inborn errors of beta-oxidation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; especially in severe renal impairment when sodium restriction is required. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Restricted sodium intake: May contain 125 mg sodium per gram of sodium phenylbutyrate; use with caution, if at all, in patients who must maintain a low sodium intake.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sucrose intolerance (Canadian labeling): Some formulations may contain sucrose; take sucrose content into consideration in patients with diabetes mellitus; avoid use in patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tablet formulation: The use of sodium phenylbutyrate tablets in children weighing &le;20 kg is not recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Use in conjunction with protein restriction diet and in some cases, essential amino acid supplementation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300066\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5673907\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9934&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May diminish the therapeutic effect of Urea Cycle Disorder Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Haloperidol may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase serum concentrations of the active metabolite(s) of Urea Cycle Disorder Agents. Specifically, concentrations of phenylacetate and phenylacetylglutamine may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Valproate Products may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221859\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5673904\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Use during pregnancy is contraindicated in the Canadian labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20688403\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sodium phenylbutyrate is excreted in breast milk. The manufacturer recommends that caution be exercised when administering sodium phenylbutyrate to nursing women. Use during breast-feeding is contraindicated in the Canadian labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5673943\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">A clinician with experience in inborn metabolism errors should manage the nutrition delivery. Medication must be used in conjunction with a protein-restricted diet and, if indicated, essential amino acid supplementation. Patients requiring calorie supplementation should receive protein-free caloric supplements.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infants with neonatal-onset ornithine transcarbamylase and carbamoylphosphate synthetase deficiency: Initially limit to a protein intake of approximately 1.6 g/kg/day. May increase (after the first 4 months of life) to 1.9 g/kg/day if tolerated. Protein tolerance will decrease with decreasing growth rate. Infants from 4 months to 1 year should receive at least 1.4 g/kg/day protein, although 1.7 g/kg/day is advisable. From 1-3 years, protein intake should be at least 1.2 g/kg/day although 1.4 g/kg/day is advisable. Citrulline supplementation is recommended at 0.17 g/kg/day or 3.8 g/m<sup>2</sup>/day; free-base arginine may be used for mild disease. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Late-onset or infants with neonatal-onset argininosuccinic acid synthetase deficiency: May initially receive age-determined minimal protein allowance; increase as tolerated based on amino acid levels. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Argininosuccinic acid synthetase deficiency: Arginine (free base) supplementation is recommended at 0.4-0.7 g/kg/day or 8.8-15.4 g/m<sup>2</sup>/day</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5674006\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood ammonia, serum proteins and plasma amino acid quantitation, serum electrolytes, CBC with differential, hepatic and renal function tests; urinalysis; monitor for physical signs/symptoms of hyperammonemia (eg, lethargy, ataxia, confusion, vomiting, seizures, and memory impairment); nutritional parameters (weight, height, head circumference, albumin, prealbumin) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5674003\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Target biochemical markers for control:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Plasma ammonia: &lt;40 micromol/L; Plasma glutamine &lt;1000 micromol/L; normal plasma levels of alanine, glycine, lysine, and arginine (except in arginase deficiency), no subnormal concentrations of essential amino acids (eg, leucine, isoleucine, valine)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221853\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium phenylbutyrate is a prodrug which is rapidly converted to phenylacetate, followed by conjugation with glutamine to form phenylacetylglutamine; phenylacetylglutamine serves as a substitute for urea as it is clears nitrogenous waste from the body when excreted in the urine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5673910\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.2 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic and renal: Phenylbutyrate, a prodrug, is metabolized to phenylacetate followed by conjugation with glutamine to phenylacetylglutamine </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Phenylbutyrate (tablets and powder): 0.76 to 0.77 hours; Phenylacetate (tablets and powder): 1.15 to 1.29 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Phenylbutyrate (tablets and powder): 1 to 1.35 hours; Phenylacetate (tablets and powder): 3.55 to 3.74 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80% to 100%, primarily as phenylacetylglutamine)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221867\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Buphenyl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 g/teaspoon (250 g): $16,353.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Sodium Phenylbutyrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 g/teaspoon (250 g): $5,611.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Buphenyl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (250): $8,178.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sodium Phenylbutyrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (250): $6,695.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539930\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ammonaps (AT, CZ, DE, DK, ES, FR, GB, HR, HU, IE, IT, LT, LV, MT, NL, NO, PL, PT, RO, SE, SI, SK);</li>\n      <li>Buphenyl (JP, KR, TW);</li>\n      <li>Pheburane (GB, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Berry GT and Steiner RD, &ldquo;Long-Term Management of Patients With Urea Cycle Disorders,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):56-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylbutyrate-drug-information/abstract-text/11148550/pubmed\" target=\"_blank\" id=\"11148550\">11148550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brusilow SW, &ldquo;Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion,&rdquo; <i>Pediatr Res</i>, 1991, 29(2):147-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylbutyrate-drug-information/abstract-text/2014149/pubmed\" target=\"_blank\" id=\"2014149\">2014149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buphenyl (sodium phenylbutyrate) [prescribing information]. Deerfield, IL: Horizon Pharma; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pheburane (sodium phenylbutyrate) [product monograph]. Blainville, Quebec, Canada: Medunik Canada; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maestri NE, Brusilow SW, Clissold DB, et al, &ldquo;Long-Term Treatment of Girls With Ornithine Transcarbamylase Deficiency,&rdquo; <i>N Engl J Med</i>, 1996, 335(12):855-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylbutyrate-drug-information/abstract-text/8778603/pubmed\" target=\"_blank\" id=\"8778603\">8778603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scaglia F, Carter S, O&rsquo;Brien WE, et al, &ldquo;Effect of Alternative Pathway Therapy on Branched Chain Amino Acid Metabolism in Urea Cycle Disorder Patients,&rdquo; <i>Mol Genet Metab</i>, 2004, 81(Suppl 1):79-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylbutyrate-drug-information/abstract-text/15050979/pubmed\" target=\"_blank\" id=\"15050979\">15050979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Summar M, &ldquo;Current Strategies for the Management of Neonatal Urea Cycle Disorders,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):30-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylbutyrate-drug-information/abstract-text/11148547/pubmed\" target=\"_blank\" id=\"11148547\">11148547</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9934 Version 101.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F221871\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F27628435\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F221884\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F221872\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F221879\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F221873\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22560101\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22560102\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F221862\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F221850\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21987534\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5674004\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F221863\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221857\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F221865\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F221854\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300066\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5673907\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F221859\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5673904\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20688403\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F5673943\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5674006\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F5674003\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221853\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5673910\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F221867\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539930\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9934|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-phenylbutyrate-patient-drug-information\" class=\"drug drug_patient\">Sodium phenylbutyrate: Patient drug information</a></li><li><a href=\"topic.htm?path=sodium-phenylbutyrate-pediatric-drug-information\" class=\"drug drug_pediatric\">Sodium phenylbutyrate: Pediatric drug information</a></li></ul></div></div>","javascript":null}